Peptides
The next-generation molecules — retatrutide, survodutide, BPC-157, and the names you will hear by 2027.
The peptides desk is where the pipeline lives. We cover the molecules in late-stage trials, the research-grade peptide grey market, the compounding legal distinctions, and the ones every reader should be able to name by 2027.
Peptides PT-141 (Bremelanotide): What the Evidence Shows
Bremelanotide (Vyleesi) is FDA-approved for one specific group of women. The benefit is real but modest, nausea is common, and "PT-141" sold as a research peptide is a different story.
Peptides BPC-157: What the Human Evidence Actually Shows
The strong-sounding claims come almost entirely from rats and mice. Here is what has — and hasn't — actually been shown in people, and what regulators say.